Portal de Periódicos da CAPES

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

2021; American Association for the Advancement of Science; Volume: 7; Issue: 31 Linguagem: Inglês

10.1126/sciadv.abh3409

2375-2548

Michael J. Peluso, Saki Takahashi, Jill Hakim, J. Daniel Kelly, Leonel Torres, Nikita S. Iyer, Keirstinne Turcios, Owen Janson, Sadie E. Munter, Cassandra Thanh, Joanna Donatelli, Christopher C. Nixon, Rebecca Hoh, Viva Tai, Emily A. Fehrman, Yanel Hernandez, Matthew A. Spinelli, Monica Gandhi, Mary-Ann Palafox, Ana Vallari, Mary A. Rodgers, John Prostko, John Hackett, Lan Trinh, Terri Wrin, Christos J. Petropoulos, Charles Y. Chiu, Philip J. Norris, Clara DiGermanio, Mars Stone, Michael P. Busch, Susanna K. Elledge, Xin Zhou, James A. Wells, Albert Shu, Theodore W. Kurtz, John E. Pak, Wesley Wu, Peter D. Burbelo, Jeffrey I. Cohen, Rachel L. Rutishauser, Jeffrey N. Martin, Steven G. Deeks, Timothy J. Henrich, Isabel Rodríguez-Barraquer, Bryan Greenhouse,

COVID-19 Clinical Research Studies

Antibody detection of prior SARS-CoV-2 infection depends on severity, assay, and timing with implications for serosurveillance.